Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia : a randomized, open-label, phase II study

Background Eltrombopag is an oral thrombopoietin receptor agonist that stimulates thrombopoiesis and shows higher exposure in East Asian patients than in non-Asian patients. We evaluated the pharmacokinetics, efficacy, and safety of eltrombopag in Japanese patients with thrombocytopenia associated with chronic liver disease (CLD).